Madsen, Christian T. http://orcid.org/0000-0003-3268-5350
Refsgaard, Jan C. http://orcid.org/0000-0002-2781-0367
Teufel, Felix G. http://orcid.org/0000-0003-1275-8065
Kjærulff, Sonny K.
Wang, Zhe
Meng, Guangjun
Jessen, Carsten http://orcid.org/0000-0002-5557-2386
Heljo, Petteri
Jiang, Qunfeng
Zhao, Xin
Wu, Bo
Zhou, Xueping http://orcid.org/0000-0002-4506-9138
Tang, Yang
Jeppesen, Jacob F.
Kelstrup, Christian D.
Buckley, Stephen T.
Tullin, Søren
Nygaard-Jensen, Jan
Chen, Xiaoli
Zhang, Fang
Olsen, Jesper V. http://orcid.org/0000-0002-4747-4938
Han, Dan
Grønborg, Mads
de Lichtenberg, Ulrik http://orcid.org/0000-0002-0985-9343
Article History
Received: 14 December 2021
Accepted: 10 October 2022
First Online: 20 October 2022
Competing interests
: The authors declare the following competing interests: The authors are or have been working for Novo Nordisk A/S, a pharmaceutical company with commercial interest in bioactive peptides for the treatment of diabetes and obesity. All authors except J.C.R, F.G.T, U.L, and J.V.O. hold minor share portions as part of their employment in Novo Nordisk. J.V.O. consults for and has research funding from Novo Nordisk.